Țară: Uniunea Europeană
Limbă: engleză
Sursă: EMA (European Medicines Agency)
lanadelumab
Takeda Pharmaceuticals International AG Ireland Branch
B06AC05
lanadelumab
Other hematological agents
Angioedemas, Hereditary
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
Revision: 12
Authorised
2018-11-22
48 B. PACKAGE LEAFLET 49 PACKAGE LEAFLET: INFORMATION FOR THE USER TAKHZYRO 150 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE lanadelumab READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU GIVE THIS MEDICATION TO THE CHILD BECAUSE IT CONTAINS IMPORTANT INFORMATION. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask the child’s doctor, pharmacist or nurse. - This medicine has been prescribed for your child or a child in your care only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as those of your child or the child you are caring for. - If the child gets any side effects, talk to their doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What TAKHZYRO is and what it is used for 2. What you need to know before giving TAKHZYRO 3. How to use TAKHZYRO 4. Possible side effects 5. How to store TAKHZYRO 6. Contents of the pack and other information 7. Instructions for use 1. WHAT TAKHZYRO IS AND WHAT IT IS USED FOR TAKHZYRO contains the active substance lanadelumab. WHAT TAKHZYRO IS USED FOR TAKHZYRO 150 mg is a medicine used in patients 2 years of age and older weighing less than 40 kg, to prevent angioedema attacks in patients with hereditary angioedema (HAE). WHAT HEREDITARY ANGIOEDEMA (HAE) IS HAE is a condition which runs in families. With this condition the patients blood does not have enough of a protein called ‘C1 inhibitor’, or C1 inhibitor does not work properly. This leads to too much ‘plasma kallikrein’, which in turn produces higher levels of ‘bradykinin’ in the bloodstream. Too much bradykinin leads to symptoms of HAE like swelling and pain on the, • hands and feet • face, eyelids, lips or tongue • voice-box (larynx), which may make breathing difficult • genitals HOW TAKHZYRO WORKS TAKHZYRO is a type of protein that blocks the activity of plasma kallikrein. This helps to reduce the amount of bradykinin in the bloodstr Citiți documentul complet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT TAKHZYRO 150 mg solution for injection in pre-filled syringe TAKHZYRO 300 mg solution for injection in pre-filled syringe TAKHZYRO 300 mg solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION TAKHZYRO 150 mg solution for injection in pre-filled syringe One unit (pre-filled syringe) contains 150 mg of lanadelumab* in 1 ml solution. TAKHZYRO 300 mg solution for injection (pre-filled syringe or vial) One unit (pre-filled syringe or vial) contains 300 mg of lanadelumab* in 2 ml solution. * Lanadelumab is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection The solution is colourless to slightly yellow, appearing either clear or slightly opalescent. The solution has a pH of approximately 6.0 and an osmolality of approximately 300 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION This medicinal product should be initiated under the supervision of a physician experienced in the management of patients with hereditary angioedema (HAE). Posology _Adults and Adolescents 12 to less than 18_ _years of age _ _ _ The recommended starting dose is 300 mg lanadelumab every 2 weeks. In patients who are stably attack free on treatment, a dose reduction to 300 mg lanadelumab every 4 weeks may be considered, especially in patients with low weight. In patients with a body weight less than 40 kg, a starting dose of 150 mg lanadelumab every 2 weeks may also be considered. In patients who are stably attack free on treatment, a dose reduction to 150 mg lanadelumab every 4 weeks may be considered. 3 _Children 2 to less than 12 years of age _ _ _ The recommended dose of lanadelumab for children 2 to less than 12 years of age is based on body weight ( Citiți documentul complet